<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568878</url>
  </required_header>
  <id_info>
    <org_study_id>01</org_study_id>
    <nct_id>NCT02568878</nct_id>
  </id_info>
  <brief_title>Creatine for Depressed Male and Female Methamphetamine Users</brief_title>
  <official_title>An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montana State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montana State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Assess the antidepressant/anxiolytic effect of creatine in male and female
           methamphetamine users

        -  Assess creatine's effect on methamphetamine use

        -  Assess the safety of creatine in male methamphetamine users with depression
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD) Scores</measure>
    <time_frame>This data will be assessed after 12 participants have completed the study and again after a completed sample size of 24 is achieved. The data will be presented at study completion (anticipated: 12 months after study initiation).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAMA) Scores</measure>
    <time_frame>This data will be assessed after 12 participants have completed the study and again after a completed sample size of 24 is achieved. The data will be presented at study completion (anticipated: 12 months after study initiation).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported methamphetamine use</measure>
    <time_frame>This data will be assessed after 12 participants have completed the study and again after a completed sample size of 24 is achieved. The data will be presented at study completion (anticipated: 12 months after study initiation).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Adverse events will be reviewed monthly for safety concerns and presented at study completed (anticipated: 12 months after study initiation).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of positive urine drug screens for methamphetamine</measure>
    <time_frame>This data will be assessed after 12 participants have completed the study and again after a completed sample size of 24 is achieved. The data will be presented at study completion (anticipated: 12 months after study initiation).</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <condition>Methamphetamine Dependence</condition>
  <arm_group>
    <arm_group_label>Creatine monohydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 grams of daily creatine monohydrate by mouth for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creatine monohydrate</intervention_name>
    <arm_group_label>Creatine monohydrate</arm_group_label>
    <other_name>Creapure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine
             preferred drug of abuse

          -  Current diagnosis of major depressive disorder (primary or substance-induced)

          -  Current diagnosis of an anxiety disorder (primary or substance-induced)

          -  Current Hamilton Depression Rating scale score &gt; or = to 16

          -  Current Hamilton Anxiety Scale score &gt; = to 18

          -  If taking a psychotropic medication for depressed or anxious mood, regimen must be
             stable for &gt; = to 4 weeks prior to creatine treatment initiation

        Exclusion Criteria:

          -  Persons unable to provide adequate informed consent

          -  Persons who are at clinically significant suicidal or homicidal risk

          -  Primary substance-related diagnosis other than methamphetamine dependence or abuse

          -  Positive pregnancy test (females only)

          -  History of renal disease

          -  Clinically significant medical or neurological illness identified by history, physical
             exam and laboratory testing

          -  History of hypersensitivity reaction to creatine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracy Hellem, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montana State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tracy Hellem, PhD</last_name>
    <phone>406 243 2110</phone>
    <email>tracy.hellem1@montana.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montana State University College of Nursing (Missoula campus)</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59812</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Hellem, PhD</last_name>
      <phone>406-243-2110</phone>
      <email>tracy.Hellem1@montana.edu</email>
    </contact>
    <contact_backup>
      <phone>4062432110</phone>
    </contact_backup>
    <investigator>
      <last_name>Tracy Hellem, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2015</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montana State University</investigator_affiliation>
    <investigator_full_name>Tracy Hellem</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Methamphetamine dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

